Regulatory agencies such as the FDA, DEA, and international bodies are actively working to address the synthetic opioid crisis. Measures include classifying certain synthetic opioids as Schedule I substances, increasing surveillance of drug distribution networks, and promoting the availability of naloxone. Public health initiatives also focus on education, prevention, and treatment programs to reduce the impact of opioid addiction.
